Replies to post #170311 on Biotech Values

[DewDiligence]

Re: Restricting reimbursement for HCV treatment

What's so medically and politically dangerous about requiring a fibrosis test to assess liver damage before spending $100k to treat the cause of it?

Under your scheme, when do you retest if the results of the initial test are negative? In 2 years? 3 years? 5 years? Never? No matter how you do it, some patients will walk away, never get treatment, and progress to HCC or a transplant.

Moreover, as noted in #msg-94307715, the actual ASP of all-oral HCV regimens will not be >=$100K, no matter how high the nominal list price might be.